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Abstract
Background: MMP28 (epilysin) is a recently discovered member of the MMP (matrix metalloproteinase) family that
is, amongst others, expressed in osteoarthritic cartilage and intervertebral disc (IVD) tissue. In this study the
hypothesis that increased expression of MMP28 correlates with higher grades of degeneration and is stimulated by
the presence of proinflammatory molecules was tested. Gene expression levels of MMP28 were investigated in
traumatic and degenerative human IVD tissue and correlated to the type of disease and the degree of
degeneration (Thompson grade). Quantification of MMP28 gene expression in human IVD tissue or in isolated cells
after stimulation with the inflammatory mediators lipopolysaccharide (LPS), interleukin (IL)-1b, tumor necrosis factor
(TNF)-a or the histondeacetylase inhibitor trichostatin A was performed by real-time RT PCR.
Results: While MMP28 expression was increased in individual cases with trauma or disc degeneration, there was
no significant correlation between the grade of disease and MMP28 expression. Stimulation with LPS, IL-1b, TNF-a
or trichostatin A did not alter MMP28 gene expression at any investigated time point or any concentration.
Conclusions: Our results demonstrate that gene expression of MMP28 in the IVD is not regulated by inflammatory
mechanisms, is donor-dependent and cannot be positively or negatively linked to the grade of degeneration and
only weakly to the occurrence of trauma. New hypotheses and future studies are needed to find the role of
MMP28 in the intervertebral disc.
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Background
Proteins of the matrix metalloproteinase (MMP) family
play an essential role in tissue homeostasis by initiating
breakdown and reorganization of the extracellular matrix.
While being tightly regulated in normal physiological
processes (e.g. via tissue inhibitors of metalloproteases
TIMPs), dysregulation of MMPs has been implicated in
many diseases. During intervertebral disc (IVD) degen-
eration, the expression and activity of a number of
MMPs is increased, including MMPs 1, 3, 7, 9 and 13 [1].
Proinflammatory cytokines such as IL-1b and TNF-a as
well as bacterial endotoxins (e.g. lipopolysaccharide LPS)
can stimulate expression of various MMPs (e.g. MMPs 1,
3, 9 and 13) in the IVD, as well as in cartilage [2-10].
During the recent past, five new members in the
MMP family have been identified: MMP24 to MMP28.
MMP28, also known as epilysin and most closely related
to MMP19, is a soluble MMP that contains an activa-
tion sequence recognized by the furin endoprotease
following the pro-domain [11]. It is a well-conserved
MMP, with great similarity (97%) in the catalytic
domain between human and mouse and overall 85%
identical amino acids [12]. MMP28 is strongly expressed
in testis, as well as in bone, kidneys, lung, heart, colon,
intestines, brain, skin and carcinomas [12-17]. It is also
expressed in cartilage, synovium and IVDs, with lower
expression in bovine discs compared to bovine cartilage
[18-22]. Interestingly, MMP28 expression seemed to be
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pared to healthy tissue, indicating that it may play an
important role during these disease processes [18-21].
Despite increasing interest in the role of MMP28 in
vivo, little is known about its substrates. Recombinant
MMP28 has been reported to degrade casein in vitro
and is thought to cleave several neural proteins such as
neurite outgrowth inhibitor A ( = Nogo-A), neural cell
adhesion molecule ( = NCAM-1) and neuregulin 1 ( =
NRG1) [17,23,24]. However, with regard to musculoske-
letally relevant proteins, no information on potential
substrates is currently available.
As symptomatic degenerated IVDs are characterized
by increased levels of certain proinflammatory mediators
[10,25-27], which are know to regulate several MMPs
[1], we hypothesized that MMP28 expression could be
increased in an inflammatory context. Therefore, the
aim of this study was to determine the expression level
of MMP28 in traumatic or degenerated discs (with dif-
ferent degrees of degeneration) and to investigate the
effects of different concentrations of the proinflamma-
tory mediators IL-1b,T N F - a or LPS on its expression
in human IVD cells at various time points. Additionally,
the effect of the histondeacetylase (HDAC) inhibitor tri-
chostatin A was investigated, as it has been shown to be
an up-regulator of MMP28 expression in HeLa cells
[28].
Materials and methods
MMP28 expression in human IVD biopsies
Thirteen tissue samples from eight patients who had been
diagnosed with symptomatic degenerative disc disease or
spinal trauma were included in this part of the study.
Based on magnetic resonance imaging (MRI) findings, the
degree of IVD degeneration was evaluated according to the
Thompson grading system prior to the surgical interven-
tion (for detailed information see Table 1) [29]. Informed
consent was obtained from all patients according to the
local ethical regulations. Frozen biopsies were pulverized,
the IVD fragment powder was dissolved in 1 ml of TriFast
RNA isolation reagent (PeqLAB) and total RNA was iso-
lated according to the manufacturer’s instructions. cDNA
was prepared from total RNA using VILO cDNA Synthesis
Kit (Invitrogen). For Real-Time (RT)-PCR, cDNA template
(5 μl) was mixed with the qPCR reaction solution (IQ
SYBR Green Supermix, Bio Rad) and expression of
GAPDH and MMP28 was measured:
GAPDH: Forward-TGGACTCCACGACGTACTCA
GAPDH: Reverse-GGAAGCTTGTCATCAATGGAA
MMP28: Forward-GCCGTGCAGAGCCTGTAT
MMP28: Reverse-GAGTCCCAGGTCTCAAAGTCA
Furthermore, MMP13 was measured as a control gene:
MMP13: Forward-CCAGTCTCCGAGGAGAAACA
MMP13: Reverse-AAAAACAGCTCCGCATCAAC
Primers were used at a concentration of 0.25 nΜ, reac-
tions were carried out in triplicates and the specificity of
the amplification products was controlled with a melting
curve analysis of each reaction. The 2
-ΔCt method was
used to calculate gene expression levels of MMP28 and
MMP13. To assure consistent PCR quality, a functional
cDNA quality control was used. Samples that produced
Ct values for GAPDH greater than 26 were not included
in the analysis. Instead PCR was repeated with a new
sample with identical Thompson grade.
Isolation, culture and stimulation of IVD cells
Twenty patients who had been diagnosed with sympto-
matic disc disease or disc herniation (for detailed
Table 1 Clinical and demographic data of the study
population used for ex vivo gene expression analysis
(age, sex, diagnosis, Thompson grade [29], vertebral
level)
Sample Sex Age Diagnosis Grade Level Region
1 M 31 DDD II L5/S1 NP
2a F 39 Trauma II C4/5 AF
2b F 39 Trauma II C4/5 NP
3a F 57 Trauma II Th10/11 AF
3b F 57 Trauma II Th10/11 NP
4a F 70 Trauma II Th12/L1 AF
4b F 70 Trauma II Th12/L1 NP
5a M 29 Trauma III L1/2 AF
5b M 29 Trauma III L1/2 NP
6a F 34 DDD III L4/5 AF
6b F 34 DDD III L4/5 NP
7a M 41 DDD III C4/5 AF
7b M 41 DDD III C4/5 NP
8 M 46 DDD III L5/6 NP
9a M 25 DDD IV L5/S1 AF
9b M 25 DDD IV L5/S1 NP
10 M 44 DDD IV L5/S1 AF+NP
11 M 50 DDD IV L5/S1 AF+NP
12 M 55 Spondylodesis IV C3/4 AF+NP
13a F 58 Spondylodesis IV C5/6 AF
13b F 58 Spondylodesis IV C5/6 NP
14 M 37 DDD V L5/S1 AF+NP
15a F 41 DDD V L3/4 AF
15b F 41 DDD V L3/4 NP
16a M 67 DDD V L5/S1 AF
16b M 67 DDD V L5/S1 NP
17a M 72 DDD V L4/5 AF
17b M 72 DDD V L4/5 NP
M = male, F = female, NP = nucleus pulposus, AF = annulus fibrosus. DDD =
degenerative disc disease, C = cervical, Th = thoracic, L = lumbar, S = sacral
(degeneration grade according to Thompson)
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treatment were included in this cell culture study.
Informed consent was obtained from all patients accord-
ing to the local ethical regulations. Disc tissue was
minced and treated with 0.3% collagenase NB4 (Serva)
and 0.2% dispase II (Roche Diagnostics) in phosphate
buffered saline (PBS) for approximately 6 hours at 37°C.
After digestion, the cell suspension was filtered using a
70 μm cell strainer (BD Bioscience, Switzerland), centri-
fuged at 1000 g for 5 min and the cell pellet was washed
with and then resuspended in DMEM/F12 (Sigma). Cells
were expanded in a 2D culture containing DMEM/F12
(Sigma) with 10% FCS (Tecomedical), penicillin (50 U/
mL), streptomycin (50 μg/mL), and ampicillin (125 ng/
mL) (Gibco), with medium changes twice a week. When
an 80% confluence level was reached, expanded cells in
passage 2 or 3 were rendered serum free for 2 hours and,
in a first set of experiments, incubated with LPS, IL-1b
and TNF-a in a time-dependent (n = 5) and dose-depen-
dent manner (n = 5). For the dose dependency experi-
ment, cells were treated for 18 hours with different
concentrations of LPS (0.01 μg/ml, 0.1 μg/ml, 1.0 μg/ml,
2.0 μg/ml), IL-1b (0.1 ng/ml, 1 ng/ml, 5 ng/ml, 10 ng/ml)
or TNF-a (0.1 ng/ml, 1 ng/ml, 10 ng/ml, 100 ng/ml). For
the time course experiment, cells were incubated with one
chosen concentration of LPS (1 μg/ml), IL-1b (5 ng/ml) or
TNF-a (100 ng/ml) for 2, 6 or 18 hours in serum-free
medium. In a second set of experiments, disc cells as well
as HeLa cells (positive control) were incubated with differ-
ent concentrations of the HDAC inhibitor trichostatin A
(1 nM, 10 nM, 100 nM, 1000 nM) (Sigma-Aldrich) for 18
h o u r s( n=3 ) .A st r i c h o s t a t i nAi sd i s s o l v e di nE t O H ,a
respective EtOH control was included in these experi-
ments. All concentrations of all chemicals were shown to
be non-toxic in advance using the MTT assay (data not
shown).
MMP28 mRNA detection in isolated human IVD cells after
stimulation
After stimulation, cells were trypsinized and total RNA
was isolated according to the manufacturer’s recommen-
dation (PureLink RNA Mini Kit, Invitrogen). For each
sample, 1 μg of total RNA was reverse transcribed to
cDNA (Reverse Transcription Reagents, Applied Biosys-
tems) and then used for real-time RT-PCR measurements
using TaqMan Gene Expression assays (Applied Biosys-
tems) for detection of MMP28 (Hs00425233_m1) as well
as of TATA-box binding protein TBP (internal control)
(Hs00427620_m1). As a positive control, expression of
MMP13 was also measured (Hs00233992_m1) on samples
stimulated with IL-1b (10 ng/ml), LPS (2.0 μg/ml) or
TNF-a (100 ng/ml) for 18 hours.
Gene expression was first normalized to the house-
keeping gene before comparing expression of treated
cells to untreated control or the respective solvents con-
trol if applicable (2
-ΔΔCt method). Only changes > 2-fold
were considered to be relevant.
Statistical analysis
To compare gene expression levels between the study
groups, the Wilcoxon signed-rank test was used to
determine significance between the groups. The statisti-
cal software package SPSS was used and the significance
level was set to p < 0.05
Results
MMP28 gene expression pattern in human disc tissue
Analysis of MMP28 gene expression in disc biopsies,
which was grouped according to the degree of IVD
degeneration (Thompson grade), is shown in Figure 1a:
MMP28 was expressed in most of the analyzed disc sam-
ples and higher expression levels were found in samples
removed because of spine trauma (Thomson grade II =
normal adult discs with no disc degeneration). Expression
levels were low or practically absent in samples with
Thompson grade III (i.e. mild disc degeneration), but
increased slightly with increasing disc degeneration, with
high donor-donor variation. No consistent statistically
Table 2 Clinical and demographic data of the study
population used for in vitro cell culture experiments
(age, sex, diagnosis, Pfirrmann grade [38], vertebral
level)
Sample Age Sex Diagnosis Grade Level
1 59 F Disc Herniation 4 L4/5
2 61 M Disc Herniation 4 L3/4
3 50 M Disc Herniation 3 L5/S1
4 46 F Disc Herniation 5 L5/S1
5 51 M Symptomatic Disc Disease 3 L4/5
6 50 F Disc Herniation 3 L3/4
7 51 F Disc Herniation 3 L4/5
8 47 M Disc Herniation 5 L4/5
9 42 M Disc Herniation 4 L4/5
10 80 M Disc Herniation 4 L2/3
11 50 M Disc Herniation 4 L4/5
12 48 F Symptomatic Disc Disease 3 L4/5
13 61 F Disc Herniation 4 L4/5
14 37 F Disc Herniation 4 L4/5
15 66 M Disc Herniation 3 L5/S1
16 70 F Disc Herniation 4 L5/S1
17 40 F Disc Herniation 4 L4/5
18 55 F Disc Herniation 3 L4/5
19 26 M Disc Herniation 4 L5/S1
20 57 M Disc Herniation 4 L4/5
M = male, F = female, L = lumbar, S = sacral (grading according to Pfirrmann)
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Thompson grades or disease could be found (Figure 1a).
As a control gene, MMP13 expression was analyzed in
the same samples, and it showed a strong increase in
expression in samples with Thompson grade V degenera-
tion (Figure 1b), as previously described in the literature
[30,31].
Regulation of MMP28 gene expression
No changes in MMP28 expression could be observed
when cells were treated with different concentrations of
LPS (Figure 2a), IL-1b (Figure 2b) or TNF-a (Figure 2c)
for 18 hours, no matter which concentration was used.
As changes in gene expression may strongly depend on
the chosen time point, one concentration that is typi-
cally used in the literature was chosen for each inflam-
matory mediator and cellular behavior was investigated
after 2, 6 or 18 hours of treatment. However, even at
different time points, MMP28 expression was not regu-
lated by LPS (1 μg/ml) (Figure 3a), IL-1b (5 ng/ml)
(Figure 3b) or TNF-a (100 ng/ml) (Figure 3c). In order
to verify the general responsiveness of disc cells to the
chosen treatment conditions, we also measured changes
in MMP13 expression. We found that after 18 hour,
treatment with IL-1b (100 ng/ml) resulted in a 146.4 ±
28.0 fold increase of MMP13 expression. Similarly, LPS
(2.0 μg/ml) caused an 11.1 ± 2.2 fold increase and TNF-
a (100 ng/ml) a 134.0 ± 31.5 fold increase in MMP13
mRNA levels (Mean ± SEM, all p < 0.001)(data not
shown).
Trichostatin A (a HDAC inhibitor) did not cause any
changes in MMP28 expression in human IVD cells at
any concentration (18 hours only) (Figure 4a). However,
in HeLa cells, which were used as a positive control,
Trichostatin A caused a significant 2.1 ± 0.1 fold induc-
tion of MMP28 expression at 1000 nM (p < 0.001)(data
not shown).
Discussion
Our results indicate that MMP28 is expressed by human
intervertebral disc cells in vivo and in vitro, with high
donor-donor variations in vivo but did not depend on
the level of disc degeneration as measured by Thomp-
son grade score. Additionally, we were able to demon-
strate that inflammatory cues (LPS, IL-1b and TNF-a)
did not regulate the expression of MMP28 in vitro, indi-
cating that inflammatory processes during IVD disease
do not seem to regulate MMP28 expression in vivo.
In our study, MMP28 was expressed in most disc sam-
ples with overall more pronounced expression in virtually
non-degenerated (grade II), traumatic tissue (removed for
the need of spinal fusion after trauma) and severely degen-
erated IVD tissue. However, for both, non-degenerated tis-
sue and the severe degeneration group, high donor-donor
variation was observed. Differences in expression levels in
similarly degenerated discs suggest that individual pro-
cesses during degeneration rather than the degeneration
stage itself causes an up-regulation of MMP28. In a study
done by Gruber et al., MMP28 was measured on the gene
expression level using Affymetrix gene array as well as on
the protein level using immunohistochemistry on discs
with Thompson grade I to IV [19]. Protein detection of
MMP28 expression was also anticipated in our study, but
commercially available antibodies proved to be unspecific
when performing immunoblotting experiments (data not
s h o w n ) .C o m p a r a b l et oo u rs t u d y ,G r u b e re ta l .d e m o n -
strated that gene expression of MMP28-precursor (gene
identification number AF219624.1) tended to be highest in
Thompson grade I and II trauma discs and also elevated
in severely degenerated and herniated discs, again without
any statistical correlation. Therefore, it is still unclear to
Figure 1 Ex vivo human IVD tissue gene expression of a)
MMP28 and b) MMP13 ( = positive control) in degenerated or
traumatic samples with Thompson grading II-V (patients: n =
17, samples: n = 28). Data is presented as individual measurement
values; * if p < 0.05 between indicated groups.
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expression levels. However, increased levels of MMP28
could be detected in cartilage from osteoarthritis and
rheumatoid arthritis patients, suggesting that this novel
MMP plays a certain, not completely understood role in
some musculoskeletal diseases [18,20,21]. So far, it is not
clear why some trauma patients showed high MMP28
expression, but it has been described that certain MMPs
such as MMP1 may also increase in disc tissue after trau-
matic incidences [31,32]. The molecular mechanisms
underlying the peculiar expression of MMP28 during
trauma and certain cases of more severe degeneration is
not clear yet and will have to be analyzed further. During
degeneration and trauma, specific molecular events may
take place, such as apoptotic or inflammatory processes,
changes in matrix protein composition (e.g. increase in
collagen type I) and alterations in the mechanical environ-
ment [32-36], all of which may explain MMP28 regulation.
Aside from MMP28, we also measured MMP13 expres-
sion, whose levels have been described in the literature to
be elevated with degeneration [30,31]. In our samples, we
also found a significant and relatively high increase of
MMP13 expression in the grade V degeneration group,
compared to all lower grades of degeneration, thus con-
firming previously published data.
However, when testing whether inflammation regulates
MMP28 expression, we could not find any changes in
MMP28 mRNA levels after treatment with LPS, IL-1b or
TNF-a, although inflammatory mediators regulate many
other MMPs (e.g. MMP1, MMP3, MMP9, MMP13), as
shown in the literature [7-10]. Indeed, when measuring
changes in MMP13 expression in our samples, we were
able to detect a significant increase after stimulation with
all three agents (LPS, IL-1b or TNF-a). This clearly indi-
cates that the absence of MMP28 regulation observed in
this study is not due to lack of sensitivity of our model
system. As effects on gene expression after stimulation
can depend strongly on the used concentrations as well
as on the chosen time point for analysis, variations in
dose and sampling points were considered in this study,
yet no effects were observed under any condition. In
human keratinocytes, TNF-a induced MMP28 at least to
a minor degree (up to 8 fold), while multiple other
growth factors (bFGF, EGF, GM-CSF, HGF, KGF, PDGF,
TGF-b1, VEGF, IGF-1) and cytokines (IFN-g,I L - 1 b)d i d
not influence its expression levels at all [37]. All this data
indicates that compared to other MMPs, MMP28 seems
to be rather unresponsive to external inflammatory sti-
muli in disc cells, although being expressed in degenera-
tive diseases that are characterized by inflammation.
Figure 2 Regulation of MMP28 gene expression in human IVD cells treated with different concentrations of LPS (a), IL-1b (b) or TNF-a
(c) for 18 hours (n = 5 each). Data is presented as mean ± SEM; * if p < 0.05 between indicated groups.
Figure 3 Regulation of MMP28 gene expression in human IVD cells treated with 1 μg/ml LPS (a), 5 ng/ml IL-1b (b) or 10 ng/ml TNF-a
(c) for 2, 6 or 18 hours (n = 5 each). Data is presented as mean ± SEM; * if p < 0.05 between indicated groups.
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no distinction was made between annulus fibrosus and
nucleus pulposus cells as a clear separation of the two
zones is not possible in later stage degenerated disc tissue
(whereas a separation was possible in less degraded tissue
in the first part). Considering the fact that no effect was
observed in this mixed cell population, it is however unli-
kely that a significant alteration would have been
observed if distinct cell types had been used.
As TNF-a was not able to induce MMP28 in human
IVD cells, we investigated the potential of trichostatin A, a
HDAC inhibitor, which was previously shown to strongly
regulate MMP28 in HeLa cells. It is assumed that HDAC
inhibitors induce MMP28 promoter by acetylation of spe-
cificity protein 1 (SP1), which can alter protein-protein
interactions and can modify the SP1 containing protein
complexes that act at the GC/GT-boxes [28]. However, in
our experiments, trichostatin A did not have any effect on
the expression levels of MMP28 in disc cells, but the sti-
mulatory effect in HeLa cells could be confirmed in our
experimental setting. So far, no other studies have been
performed concerning the responsiveness of MMP28 to
HDAC inhibitors. Therefore, it is unknown whether most
other cell types would show a behavior similar to HeLa
cells (regulation) or to IVD cells (no regulation).
Conclusions
In conclusion, findings of this study provide evidence
that MMP28 expression in human IVD tissue is higher
in certain cases but the causal relationship between disc
diseases and MMP28 expression is unclear to date. In
contrast to many other MMPs, MMP28 is not regulated
by various inflammatory mediators (IL-1b,T N F - a,L P S )
or the HDAC inhibitor trichostatin A. Future studies
will be necessary to identify the role of MMP28 in the
IVD more conclusively.
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